“抗血清第一股”有望诞生?江西生物欲叩开港交所大门

e公司
22 May

在生物医药这条持续增长的赛道中,抗血清作为公共卫生体系不可或缺的一环,长期被市场低估,隐匿于主流关注之外。目前,国内抗血清领域生产企业屈指可数,产业与技术门槛构筑起深厚壁垒,让该赛道成为兼具稀缺性与广阔前景的投资高地。其中,江西生物制品研究所股份有限公司(“江西生物”)凭借多年深耕,已然成长为行业龙头。根据弗若斯特沙利文的资料,按2024年销量计,江西生物以65.8%及36.6%的市场份额,成为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10